P3.03-030 TP53 Alteration, a Potential Primary Cause of Early Progression in EGFR-Mutated NSCLC Patients Treated with First-Line TKIs

Y. Xu; Z. Huang; H. Lu; Y. Fan

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P3.03-030 TP53 Alteration, a Potential Primary Cause of Early Progression in EGFR-Mutated NSCLC Patients Treated with First-Line TKIs

【24h】

P3.03-030 TP53 Alteration, a Potential Primary Cause of Early Progression in EGFR-Mutated NSCLC Patients Treated with First-Line TKIs

机译：P3.03-030 TP53改变，近期TKIS治疗EGFR突变的NSCLC患者早期进展的潜在原因

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2017年第11期|共1页
作者
Y. Xu; Z. Huang; H. Lu; Y. Fan;
展开▼
作者单位

Chemotherapy Zhejiang Cancer Hospital;

Chemotherapy Zhejiang Cancer Hospital;

Chemotherapy Zhejiang Cancer Hospital;

Chemotherapy Zhejiang Cancer Hospital;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. P3.03-030 TP53 Alteration, a Potential Primary Cause of Early Progression in EGFR-Mutated NSCLC Patients Treated with First-Line TKIs [J] . Y. Xu, Z. Huang, H. Lu, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：P3.03-030 TP53改变，近期TKIS治疗EGFR突变的NSCLC患者早期进展的潜在原因
2. P3.02b-006 Role of TP53 Mutations in Determining Primary Resistance to First-Line Tyrosine Kinase Inhibitors in EGFR-Mutated NSCLC Patients [J] . Paola Ulivi, Matteo Canale, Angelo Delmonte, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P3.02B-006 TP53突变在EGFR-突变的NSCLC患者中确定初级抗酪氨酸激酶抑制剂的作用
3. P1.03-018 FDG-PET/CT in Patients with EGFR-Mutated NSCLC Treated with TKI. Can We Identify Early Lesions at Higher Risk of Progression? [J] . Gegory Petyt, Dimitri Bellevre, Amaury Adens, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：用TKI处理EGFR-突变的NSCLC患者的P1.03-018 FDG-PET / CT。我们可以在更高的进展风险下识别早期病变吗？
4. Delta-Radiomics Signature For Prediction Of Survival In Advanced Nsclc Patients Treated With Immunotherapy [C] . B. Farina, A. D. Ramos Guerra, C. Palacios Miras, IEEE International Symposium on Biomedical Imaging . 2021

机译：用于预测免疫疗法治疗的高级NSCLC患者存活的三角洲 - 辐射瘤
5. Preventing progression of end stage renal disease: A systematic review of patient-provider communication in primary care. [D] . Prieto, Roseanne. 2016

机译：预防终末期肾脏疾病的进展：初级保健中患者与提供者之间的交流的系统综述。
6. Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs [O] . Matteo Canale, Elisabetta Petracci, Angelo Delmonte, 2020

机译：伴有TP53突变的TKI治疗EGFR突变的非小细胞肺癌患者的预后更差
7. P1.14-05 TP53 Exon 8 Mutation and Prognosis in EGFR-Mutated NSCLC Patients Treated with First-And-Second-Generation TKIs [O] . M. Canale, E. Petracci, L. Crino, 2019

机译：P1.14-05 TP53 EXON 8突变突变的NSCLC患者突变和预后，用第一代和第二代TKIS治疗

P3.03-030 TP53 Alteration, a Potential Primary Cause of Early Progression in EGFR-Mutated NSCLC Patients Treated with First-Line TKIs

著录项

相似文献

相关主题

期刊订阅